We are maturing a diversified pipeline of technologies in-house, both proprietary and co-developed with external partners. These technologies are being developed according to our 4-stages process: proof of mechanism, proof of principle, proof of concept and proof of relevancy.
Our ongoing projects:
♦ Our balanced pipeline includes New Chemical Entities (NCE), biologics, added value generics (repositioning), fixed dose combinations;
♦ Targeting at least two indications: large market indications and niche market indications (orphan diseases);
♦ Our know-how consists of orchestrating screening, due diligence, validation, development and appropriate deal structure.